Join BIOCYTOGEN at Gene-ius Break South SF Biotech/ Biopharma Forum
BIOCYTOGEN is proud to host the Gene-ius Break in South San Francisco on September 25th! This prestigious event brings together top minds in basic and clinical science from around the globe to connect, collaborate, and share groundbreaking ideas in biotech innovation. It’s an incredible opportunity to connect with like-minded professionals and gain insights from top industry leaders.
What is the Gene-ius Break?
The Gene-ius Break unites over 60 top industry leaders, researchers, investors, and entrepreneurs from the global biotech community. With engaging talks, dynamic panel discussions, and valuable networking sessions, this event serves as a key platform to explore the latest trends and breakthrough innovations. Whether you’re a seasoned expert or new to the field, this gathering will keep you at the forefront of biotechnology’s rapid advancements. It’s the perfect opportunity to expand your network, dive into industry discussions, or simply relax and connect with peers.
Event Overview
Date: Wednesday, September 25th · 4pm – 8pm PDT
Theme: Robust in vivo models derisk clinical trials
- 4:00-4:30pm Registration
- 4:30-4:40pm Opening remark, James Jin, VP at Biocytogen.
- 4:40-5:10pm Tangsheng Yi, Ph.D, Senior Director, Inflammation Biology/Immunology Discovery, Gilead Sciences
- 5:10-5:40pm Yan Wang, Ph.D, VP, Translational Aging Biology, BioAge Labs
- 5:40-6:10pm Lulu Y. Chen, Ph.D, Assistant professor, School of Medicine, University of California, Irvine
- 6:10-8:00pm Social networking
- 6:30-8:00pm Dinner reception
Venue: Tower Place, 1 Tower Pl, South San Francisco, CA 94080
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We’re looking forward to connecting with you at the Gene-ius Break in South San Francisco!
